🔗 Share this article

While the US proceeds with unprecedented revisions to its vaccine schedules, a particular individual appears in a surprising turn: Dr. Tracy Beth Høeg, a Danish American sports physician and public health researcher who first made her name by casting doubt on COVID-19 vaccinations throughout the pandemic and has focused upon possible fatalities after Covid immunization in her short tenure at the FDA.

Planned Changes to Pediatric Vaccine Program

Health officials had intended to unveil radical changes to the pediatric vaccination calendar in December, bringing the US with the Danish immunization schedule, sources say – a substantial departure that would place the US at odds with a large portion of the international standard with insufficient data for benefit. The planned update has been pushed back until the next year.

In place of the top vaccines chief, Tracy Beth Høeg is listed to present at the event. She was recently named temporary leader of the FDA’s drug evaluation center, the fifth person to run the office this year.

A New Direction at the Agency

This interim role could signify a strengthened alliance between the pharmaceutical and vaccine branches as Høeg and Dr. Prasad strengthen their influence at the regulatory agency – and it suggests a increased emphasis upon reevaluating previously authorized immunizations at the FDA.

Dr. Høeg has frequently advocated for discontinuing specific pediatric shot schedules in the US so as to align more in line with Denmark, a country with nationalized medicine and a population approximately the size of Wisconsin’s.

In her initial statements, she has kept her attention on vaccines – traditionally the domain of Prasad, chief of the FDA’s CBER – as opposed to pharmaceutical oversight.

Concerns Over Background

Høeg has no obvious track record in drug development, regulation or administrative roles, which has been typical for past heads of the biologics center. She has served at the FDA as a top consultant to the FDA chief and CBER since earlier this year.

“She appears not to have the requisite experience” for running the pharmaceutical oversight division, said Dr. Jonathan Howard. “She lacks experience running a clinical trial. She lacks experience in leading a large organization. She lacks background in pharmaceutical oversight.”

Past heads of CBER would “be deeply familiar with regulatory frameworks and the science of medication creation”, noted Janet Woodcock. “Frankly, she lacks the type of experience that former directors who led CBER have had.”

CDER has an enormous workload at the FDA, Woodcock emphasized.

“Many people just focuses on the novel medication approvals, but the generic program approves thousands of generic drugs. There is also a biologic copycat branch, OTC medication office and so forth, and each of these have to be looked after,” she noted. “The area you overlook, that’s the thing that I always told people is going to cause problems.”

Furthermore, a substantial leadership element to the role, which supervises more than 5,000 personnel. “It’s a huge management job, if you do it right,” the former official concluded.

Official Statement and Disputed Policies

When asked about inquiries about Dr. Høeg's qualifications and whether this assignment signifies greater collaboration among FDA leaders on immunizations, a spokesperson stated that the “questions are based on flawed premises”.

“This background matches the duties of her job,” the spokesperson stated, pointing to the months Høeg spent advising the agency head on “drug safety and regulatory science, including computational safety modeling and shot safety tracking”.

In her interim role, Høeg assumes responsibility for the agency head's controversial priority voucher program, a controversial one-day medication authorization process that allegedly concerned her predecessors. “By what process are these drugs being selected for this expedited pathway? Who makes the calls?” Dr. Howard questioned. “There’s a lot of confidentiality occurring at the agency right now.”

Overall, he said, “the Food and Drug Administration appears to be shifting towards less stringent rules of most medications, with the exception of shots.”

Established History on Immunizations

Regarding immunizations, Høeg has a clearer, if concerning, past, some experts have noted. She published a research paper using unverified volunteer-provided data to assess the incidence of myocarditis following COVID-19 immunization. She advised the state of Florida surgeon general Dr. Joseph Ladapo, who reportedly have changed statistics to imply Covid vaccines are pose a greater threat than they are.

Among her “policy goals” for the current federal leadership included changing regulations for novel immunizations and discontinuing “optional” immunizations, she stated following the vote on a online show. At the FDA, Dr. Høeg has according to sources floated the idea of barring teenage boys from getting COVID-19 vaccines.

“She’s an all-around dogmatist who begins with her preconceived notions and tailors the evidence to accommodate the science in a extremely misleading, dishonest way,” Dr. Howard argued.

Gaining Influence and a “Push for Payback”

Dr. Høeg became part of fellow dissenters, {like|